When antigens stimulate the conjunctiva, immune cells such as mast cells and eosinophils are activated ... Seasonal allergic conjunctivitis, which appears frequently at the same time these ...

A later phase, driven by eosinophils, can cause the inflammation to last ... Eye itching, tearing and pain may also be present as well, and is called allergic conjunctivitis. Symptom timing, duration, ...

Objective: This study aimed to evaluate the diagnostic utility of point-of-care tear immunoglobulin E (IgE) testing in distinguishing between type I and type IV allergic conjunctivitis ... IgE ...

Conjunctivitis is usually treated locally, directly on the affected conjunctiva. Eye drops or ointments are applied to the ...

Discover a study that highlights a potentially critical role for the BDNF-NTRK2 pathway in EoE symptom development.

Patients with eosinophilic esophagitis face significant economic burdens, according to a pair of presentations at Digestive ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Symptoms of eosinophilic esophagitis are often hard ... and it may not be immediately clear that a digestive or allergic disorder is the cause. In older children and adults, swallowing ...

The Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

Gerard Criner, MD, FACP, FACCP, MATINEE investigator, highlights trial results that showed reduced exacerbations and delayed disease progression in patients with eosinophilic chronic obstructive ...

The FDA has granted approval to GSK's Nucala as an add-on maintenance treatment for adult patients suffering from inadequately controlled COPD.